Evonik Evonik

X

Find the latest Drugs in Development and Pipeline Prospector News of CHIESI USA INC.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
CHIESI USA INC
United_States_of_America Flag
Country
Country
U.S.A
Address
Address
175 Regency Woods Place, Suite 600, Cary, NC 27518
Telephone
Telephone
(888) 466-6505/6511
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

KENGREAL (cangrelor) for Injection is a P2Y12 platelet inhibitor indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce risk of MI, repeat coronary revascularization, and stent thrombosis (ST) in patients.


Lead Product(s): Cangrelor

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Kengreal

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

In the multicenter, double-blind, randomized, parallel-group, controlled study of 423 adults with CF, subjects received either mannitol 400mg or mannitol 50mg (control), twice-daily via dry powder inhaler for 26 weeks.


Lead Product(s): Mannitol API

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Bronchitol

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 17, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The unique delivery method of their xB3 platform has the potential to overcome a significant challenge in the treatment of many neurological disorders, which is the ability to cross the blood brain barrier.


Lead Product(s): Transcend-peptide

Therapeutic Area: Genetic Disease Product Name: xB3

Highest Development Status: UndisclosedProduct Type: Peptide

Recipient: Bioasis

Deal Size: $141.0 million Upfront Cash: $3.0 million

Deal Type: Licensing Agreement June 29, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Chiesi Group expands distribution network via acquisition for worldwide product rights.


Lead Product(s): Deferiprone

Therapeutic Area: Genetic Disease Product Name: Undisclosed

Highest Development Status: ApprovedProduct Type: Small molecule

Recipient: Apotex Inc

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 13, 2020

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY